Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) — VA Rating Criteria (38 CFR DC 7719)

The VA rates Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) under Diagnostic Code 7719 at the following tiers: 30%, 60%, 100%. The minimum 30% rating requires: In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors. The maximum 100% rating requires: Requiring peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy treatment.

Diagnostic Code 7719 is the VA rating identifier for Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) within 38 CFR 38 CFR § 4.117. It defines the specific symptom criteria and percentage thresholds a VA adjudicator uses to assign a disability rating. The diagnostic code is listed on a veteran's rating decision letter.

The highest schedular rating for Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) under DC 7719 is 100%. This tier requires: Requiring peripheral blood or bone marrow stem cell transplant, or continuous myelosuppressive or immunosuppressive therapy treatment. Veterans who cannot secure substantially gainful employment due to Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) alone or in combination with other service-connected conditions may also qualify for TDIU at the 100% compensation rate under 38 CFR § 4.16.

Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) is rated under 38 CFR 38 CFR § 4.117, Diagnostic Code 7719. This section is part of the Schedule for Rating Disabilities (38 CFR Part 4) and can be read in full at the eCFR website.

Secondary conditions caused or aggravated by Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) may be ratable under 38 CFR § 3.310. Veterans should work with a VSO or accredited claims agent to document the medical relationship.

Service connection for Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia) requires three elements: (1) a current diagnosis of the condition, (2) an in-service event, injury, or disease that may have caused or aggravated it, and (3) a medical nexus connecting the current diagnosis to that in-service event. A nexus letter from a treating physician or independent medical examiner is the most reliable nexus evidence. C&P exam findings can also establish nexus if adequately documented.